Başka bir renk deneyin:
Başka bir font büyüklüğü deneyin: 60% 70% 80% 90%


 


İSTER İNANIN İSTER İNANMAYIN, STATİNLER GRİP AŞILARININ ETKİSİNİ AZALTIYOR VEYA ÖNLÜYOR

İster inanın ister inanmayın! Kolesterol ilaçları (statinler) grip aşılarının (domuz gribi dahil) etkisini azaltıyor veya önlüyor!. Umarım uzmanlar bu konuda fikirlerini söylerler…Yaşlılara boşu boşuna mı aşı yapılıyor?
Using a managed care database in Georgia, Omer and colleagues[9] conducted a retrospective cohort study over nine influenza seasons (2002-2011) to assess the effect of influenza vaccination and prescription statin status on medically attended acute respiratory illness (MAARI), a commonly used indicator of the population impact of influenza. Most patients were younger than 65 years. After adjustment for prespecified variables, statin therapy was associated with reduced effectiveness of the influenza vaccine against MAARI.
In a post hoc analysis of a randomized controlled trial[10] comparing the immunogenicity of adjuvanted vs unadjuvanted influenza vaccine in people aged 65 years or older, Black and colleagues[11] performed a cross-sectional observational study of 6961 study participants to evaluate the influence of statin therapy on the immune response to influenza vaccination. The titers of antibodies to influenza were substantially lower in persons taking statins. In statin users, titers to influenza A (H1N1) were 38% lower (95% CI, 27%-50%), titers to influenza A (H3N2) were 67% lower (95% CI, 54%-80%), and titers to B strains were 38% lower (95% CI, 28%-29%) than in nonusers, regardless of the vaccine type received (adjuvanted or unadjuvanted).
Statins, which have been shown to reduce cardiovascular mortality and major vascular events,[12,13] are among the most commonly prescribed medications in the world. In the United States, more than 40% of people who are older than 65 years use statins.[14] On the other hand, influenza is associated with considerable morbidity and mortality, especially in elderly persons, raising the question of benefit vs risk of statins in terms of possible reduced efficacy of the influenza vaccine.[15]
9. Omer SB, Phadke VK, Bednarczyk RA, et al. Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness. J Infect Dis. 2015 Oct 28. [Epub ahead of print]
10. Frey SE, Reyes MR, Reynales H, et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32:5027-5034. Abstract
11. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of statins on influenza vaccine response in elderly individuals. J Infect Dis. 2015 Oct 28. [Epub ahead of print]
12. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
13. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37-45. Abstract
14. Centers for Disease Control and Prevention. Data table for Figure 17. Statin drug use in the past 30 days among adults 45 years of age and over, by sex and age: United States, 1988-1994, 1999-2002, and 2005-2008.http://www.cdc.gov/nchs/data/hus/2010/fig17.pdf Accessed January 16, 2016.
15. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status. Influenza Other Respir Viruses. 2014;8:507-515.